Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug aims to strengthen bones by cutting body acid

NCT ID NCT07473713

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called veverimer in 60 adults aged 50 and older with osteopenia (low bone density). The goal is to see if lowering acid levels in the body can reduce bone breakdown. Participants take the drug or a placebo daily or every other day for 8 weeks, with 8 clinic visits for monitoring. The study focuses on safety and finding the right dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Community dwelling adults age 50 years and older (approximately equal numbers of men and women). 2. Men should be sterile or agree to use contraception throughout the study. 3. Women must be postmenopausal, defined as no menses in the last 5 years (to reduce variability in change in bone resorption since menopause prompts a rapid increase in bone resorption). 4. Osteopenia will be defined as a bone mineral density (BMD) T-score at the lumbar spine, femoral neck, or total hip lower than -1 or higher than -2.5. 5. On a prescreening interview, candidates must report a usual diet associated with an acid load by our validated short questionnaire. 6. Estimated glomerular filtration rate (eGFR) must be 45 ml/min or greater. 7. Participants must agree not to change their exercise pattern or medication use during the study. 8. Participants must agree not to change their pattern of supplement use and not to use antacids during the study because most calcium supplements and other antacids add alkali. 9. Participants must agree to not change their eating habits or intentionally change their weight. Exclusion Criteria: 1. Normal BMD T-scores at all spine and hip sites, osteoporosis based on BMD T-score of -2.5 or less 2. Respiratory illness in last month 3. Chronic obstructive pulmonary disease (COPD) 4. Asthma 5. Nausea/vomiting in last month 6. Dysphagia 7. Malabsorption 8. Inflammatory bowel disease 9. Chronic diarrhea (defined as loose bowel movements daily) or constipation (≤ 2 stools per week) 10. Insulin-requiring diabetes or fasting plasma glucose \>125 mg/dl 11. Untreated thyroid disease 12. Cirrhosis 13. Current unstable heart disease 14. Malignancy (except non-melanoma skin cancer) or cancer therapy in last year 15. Alcohol use \>2 drinks/day. 16. Individuals who are unable to provide informed consent due to cognitive impairment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tufts Medical Center

    RECRUITING

    Boston, Massachusetts, 02111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.